Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Consulting Writer and Editor
Sarah Klein is editor of Transforming Care, a quarterly publication of The Commonwealth Fund that profiles innovative models of care, payment, and patient engagement with the potential to reshape the nation’s delivery system. She has written about health care for more than 15 years and has worked for a variety of publications, including the Los Angeles Times, Crain's Chicago Business, and American Medical News. She has an A.B. in Chinese from Washington University in St. Louis and attended the Graduate School of Journalism at the University of California, Berkeley.